Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Leflunomide 20 mg Tablets, Non-Fasting: Complete Statistical AnalysisIndependent statistical analysis of Leflunomide 20 mg Tablets, Non-Fasting: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00834405).
- Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: Complete Statistical AnalysisIndependent statistical analysis of Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Left Lateral Position Versus Supine Position in Colonoscopy: Complete Statistical AnalysisIndependent statistical analysis of Left Lateral Position Versus Supine Position in Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06664762).
- Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): Complete Statistical AnalysisIndependent statistical analysis of Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00738972).
- LEFTBASHIndependent statistical analysis of Left Bundle Area Versus Selective His Bundle Pacing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04093414).
- LEGIT_MC_EVCDAIndependent statistical analysis of AI-based Medical Device Validation for Early Melanoma Detection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06221397).
- LEIAIndependent statistical analysis of Lisdexamfetamine's Effect In ADHD in the Brain and Cognition: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02170298).
- Lemborexant Shift Work Treatment Study: Complete Statistical AnalysisIndependent statistical analysis of Lemborexant Shift Work Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05344443).
- LEMTRADA-ITPIndependent statistical analysis of Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00267059).
- Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L: primary…
- Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00759603).
- Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Lenalidomide in HTLV-1 Adult T-Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in HTLV-1 Adult T-Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01274533).
- Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00352365).
- Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM): Complete Statistical AnalysisIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LENSIndependent statistical analysis of Lowering Events in Non-proliferative Retinopathy in Scotland: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03439345).
- Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380990).
- Lenva+PembroIndependent statistical analysis of Lenvatinib and Pembrolizumab Simultaneous Combination Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03609359).
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris: Complete Statistical AnalysisIndependent statistical analysis of LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01866163).
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris: Complete Statistical AnalysisIndependent statistical analysis of LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris: primary endpoint results, effect estimate with confidence interval,…
- Less Infections for the Diabetic Foot: Complete Statistical AnalysisIndependent statistical analysis of Less Infections for the Diabetic Foot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03615807).
- LESS TEP vs. Three Port TEP for Inguinal Hernia Repair: Complete Statistical AnalysisIndependent statistical analysis of LESS TEP vs. Three Port TEP for Inguinal Hernia Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04303182).
- Lesser Tuberosity Osteotomy for Subscapularis Repair: Complete Statistical AnalysisIndependent statistical analysis of Lesser Tuberosity Osteotomy for Subscapularis Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02762903).
- Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001): Complete Statistical AnalysisIndependent statistical analysis of Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001): primary endpoint results, effect estimate with…
- LETISIndependent statistical analysis of Assessing the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy: Complete Statistical AnalysisIndependent statistical analysis of Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Leucine for Depression Study (L-DEP): Complete Statistical AnalysisIndependent statistical analysis of Leucine for Depression Study (L-DEP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03557684).
- Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04515004).
- LEUKOIndependent statistical analysis of Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD): Complete Statistical AnalysisIndependent statistical analysis of Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00147082).
- Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer: primary endpoint results, effect estimate with confidence interval,…
- LEVANT 2 Safety Registry: Complete Statistical AnalysisIndependent statistical analysis of LEVANT 2 Safety Registry: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01790243).